Search results for "CLINICAL TRIALS"

showing 10 items of 490 documents

Recommendations for assessing Patient-Reported Outcomes and Health-Related quality of life in clinical trials on allergy: a GA2LEN taskforce position…

2010

The aim of this Global Allergy and Asthma European Network (GA(2)LEN) consensus report is to provide recommendations for patient-reported outcomes (PROs) evaluation in clinical trials for allergic diseases, which constitute a global health problem in terms of physical, psychological economic and social impact. During the last 40 years, PROs have gained large consideration and use in the scientific community, to gain a better understanding of patients' subjective assessment with respect to elements concerning their health condition. They include all health-related reports coming from the patient, without involvement or interpretation by physician or others. PROs assessment should be performe…

medicine.medical_specialtyPediatricsImmunologyPopulationMEDLINEAlergiaHypersensitivity; Humans; Treatment Outcome; Clinical Trials as Topic; Quality of Life; Outcome Assessment (Health Care); Data CollectionOutcome Assessment (Health Care)Quality of life (healthcare)Outcome Assessment Health CareGlobal healthmedicineHypersensitivityHumansImmunology and AllergyeducationAsmaeducation.field_of_studyClinical Trials as Topicbusiness.industryData CollectionGa2LenGuidelinehumanitiesClinical trialTreatment OutcomeFamily medicineInclusion and exclusion criteriaQuality of LifePosition paperbusinessQualidade de VidaHuman
researchProduct

Pantoprazole: from drug metabolism to clinical relevance.

2008

Conditions requiring inhibition of acid secretion, such as gastro-oesophageal reflux disease (GORD), peptic ulcers, non-ulcer dyspepsia or the use of NSAIDs, are very common, and their prevalence is expecting to rise as they are seen predominantly amongst the elderly. Among the drugs available to inhibit acid secretion, proton pump inhibitors (PPI) have been shown to have the best efficacy-safety ratio and have been used widely.This paper was intended to provide an overall presentation of one of these PPIs, pantoprazole.This study was first intended to give an overview of pantoprazole, so a Medline search was conducted using pantoprazole as unique search term, without publication date restr…

medicine.medical_specialtyPeptic UlcerPepticRabeprazoleLansoprazoleToxicologyGastroenterology2-PyridinylmethylsulfinylbenzimidazolesEsomeprazoleInternal medicinemedicineHumansPantoprazoleOmeprazolePantoprazolePharmacologyClinical Trials as Topicbiologybusiness.industryProton Pump InhibitorsGeneral MedicineHelicobacter pyloribiology.organism_classificationAnti-Ulcer Agentsdigestive system diseasesTreatment OutcomeGastroesophageal RefluxbusinessDrug metabolismmedicine.drugExpert opinion on drug metabolismtoxicology
researchProduct

A systematic review of neuropsychiatric symptoms in mild cognitive impairment.

2009

Mild cognitive impairment (MCI) is a clinical concept proposed as an intermediate state between normal aging and dementia. This condition has multiple heterogeneous sources, including clinical presentation, etiology, and prognosis. Recently, the prevalence and associated features of neuropsychiatric symptoms (NPS) in MCI have been described. We systematically searched the PubMed database (last accessed on August 31, 2008) for articles on NPS in MCI. Included articles used strict selection criteria, and outcome variables were extracted in duplicate; of the 27 articles included, 14 (52%) used prospective cohorts. The global prevalence of NPS in MCI ranged from 35% to 85%. The most common beha…

medicine.medical_specialtyPopulationDiseaseNeuropsychological TestsIrritabilitybehavioral disciplines and activitiesAlzheimer DiseaseRisk FactorsInternal medicinemental disordersmedicineDementiaAlzheimer’s disease behavior dementia depression incidence mild cognitive impairment neuropsychiatric symptoms predictors prevalence risk factorsHumansProspective cohort studyeducationDepression (differential diagnoses)education.field_of_studyClinical Trials as TopicGeneral NeuroscienceMental DisordersGeneral Medicinemedicine.diseasePsychiatry and Mental healthClinical PsychologyEtiologyAnxietySettore MED/26 - NeurologiaGeriatrics and Gerontologymedicine.symptomPsychologyCognition DisordersClinical psychologyJournal of Alzheimer's disease : JAD
researchProduct

Pharmacogenetics and Pharmacotherapy of Military Personnel Suffering from Post-traumatic Stress Disorder

2017

Background Posttraumatic stress disorder (PTSD) is a severe problem among soldiers with combating experience difficult to treat. The pathogenesis is still not fully understood at the psychological level. Therefore, genetic research became a focus of interest. The identification of single nucleotide polymorphisms (SNPs) may help to predict, which persons are at high risk to develop PTSD as a starting point to develop novel targeted drugs for treatment. Methods We conducted a systematic review on SNPs in genes related to PTSD pathology and development of targeted pharmacological treatment options based on PubMed database searches. We focused on clinical trials with military personnel. Results…

medicine.medical_specialtyPopulationTropomyosin receptor kinase BBioinformaticsArticleStress Disorders Post-Traumatic03 medical and health sciencessingle nucleotide polymorphisms0302 clinical medicinePharmacotherapyDopamineDopamine receptor D2medicineAnimalsHumansPharmacology (medical)geneticsGenetic Predisposition to DiseaseReceptorPsychiatryeducationeducation.field_of_studyClinical Trials as Topicbusiness.industryTraumatic stressGeneral MedicineDNAgene-environment interactions030227 psychiatryPsychiatry and Mental healthMilitary PersonnelNeurologyGene-Environment InteractionNeurology (clinical)pharmacologybusinessmental diseases030217 neurology & neurosurgeryPharmacogeneticsmedicine.drugCurrent Neuropharmacology
researchProduct

Iron Chelation Therapy in thalassaemia major: a sistematic review with meta-analyses of 1520 patients included on randomized clinical trials

2011

The effectiveness of deferoxamine (DFO), deferiprone (DFP), or deferasirox (DFX) in thalassemia major was assessed. Outcomes were reported as means±SD, mean differences with 95% CI, or standardized mean differences. Statistical heterogeneity was tested using χ2 (Q) and I2. Sources of bias and Grading of Recommendations Assessment, Development and Evaluation system (GRADE) were considered. Overall, 1520 patients were included. Only 7.4% of trials were free of bias. Overall measurements suggest low trial quality (GRADE). The meta-analysis suggests lower final liver iron concentrations during associated versus monotherapy treatment (p<0.0001), increases in serum ferritin levels during DFX 5, 1…

medicine.medical_specialtyPyridonesIronMEDLINEThalassemiaSiderophoresDeferoxamineIron Chelating AgentsChelation treatment thalassaemia clinical trials iron overload meta-analysisBenzoatesGastroenterologylaw.inventionchemistry.chemical_compoundRandomized controlled triallawInternal medicinemedicineHumansVentricular FunctionDeferiproneMolecular BiologyRandomized Controlled Trials as TopicEjection fractionbusiness.industryMyocardiumbeta-ThalassemiaDeferasiroxBeta thalassemiaCell BiologyHematologyTriazolesmedicine.diseaseChelation TherapySurgeryDeferoxamineDeferasiroxTreatment OutcomeLiverchemistryMeta-analysisFerritinsMolecular MedicineDrug Therapy CombinationbusinessDeferipronemedicine.drug
researchProduct

Quality assurance in the treatment of colorectal cancer: the EURECCA initiative

2014

Colorectal cancer is one of the most common cancers in Europe. Over the past few decades, important advances have been made in screening, staging and treatment of colorectal cancer. However, considerable variation between and within European countries remains, which implies that further improvements are possible. The most important remaining question now is: when are we, health care professionals, delivering the best available care to patients with colon or rectal cancer? Currently, quality assurance is a major issue in colorectal cancer care and quality assurance awareness is developing in almost all disciplines involved in the treatment of colorectal cancer patients. Quality assurance has…

medicine.medical_specialtyQuality managementQuality Assurance Health CareColorectal cancercolorectal cancerauditAuditquality assurancemultidisciplinarityFeedbackHealth caremedicineHumansguidelinesIntensive care medicineQuality of Health CareSettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIAClinical Trials as TopicClinical Auditbusiness.industryCancerHematologyGuidelinemedicine.diseaseSurgeryEuropeClinical trialOncologyData Interpretation StatisticalPractice Guidelines as TopicColorectal NeoplasmsbusinessQuality assurance
researchProduct

Is 5-ASA Still the Treatment of Choice for Ulcerative Colitis?

2010

5-Amino-salacylic acid (5-ASA) is up to now the treatment of choice in the induction and maintenance of remission of mild-to-moderate ulcerative colitis (UC). Sulfasalazine, despite similar efficacy, is hampered by more side effects, but in presence of peripheral arthopaties it remains the treatment of choice. The new delayed release MMX formulation seems to be promising in reducing compliance problems, but further studies are warranted to show the superiority of new MMX formulation compared with the older formulations of 5-ASA. Some trials evaluated also the efficacy and safety of once-daily dosing of older 5-ASA formulations in maintenance of remission, finding a greater adherence to ther…

medicine.medical_specialtySettore MED/09 - Medicina InternaClinical BiochemistryPharmacologyPlaceboSulfasalazineInternal medicineDrug DiscoverymedicineHumansDosingColitisMesalamine5-ASA Treatment Choice Ulcerative ColitisPharmacologyClinical Trials as Topicbusiness.industryAnti-Inflammatory Agents Non-Steroidalmedicine.diseaseUlcerative colitisTacrolimusRegimenMolecular MedicineColitis UlcerativeRosiglitazonebusinessmedicine.drugCurrent Drug Targets
researchProduct

CD4saurus Rex & HIVelociraptor vs. development of clinically useful immunological markers: a Jurassic tale of frozen evolution.

2011

Abstract One of the most neglected areas of everyday clinical practice for HIV physicians is unexpectedly represented by CD4 T cell counts when used as an aid to clinical decisions. All who care for HIV patients believe that CD4+ T cell counts are a reliable method to evaluate a patient immune status. There is however a fatalistic acceptance that besides its general usefulness, CD4+ T cell counts have relevant clincal and immunological limits. Shortcomings of CD4 counts appear in certain clinical scenarios including identification of immunological nonresponders, subsequent development of cancer on antiretroviral teatment, failure on tretment simplification. Historical and recently described…

medicine.medical_specialtyT cellantiviral treatmentHuman immunodeficiency virus (HIV)lcsh:MedicineHIV; AIDS; CD4Diseasemedicine.disease_causeGeneral Biochemistry Genetics and Molecular BiologyCD4+T cellsImmune systemAcquired immunodeficiency syndrome (AIDS)medicineIntensive care medicineMedicine(all)clinical trialsImmune statusBiochemistry Genetics and Molecular Biology(all)business.industrylcsh:RCancerimmune reconstitutionGeneral Medicinemedicine.diseaseClinical trialmedicine.anatomical_structureImmunologyCommentarybusiness
researchProduct

Recent clinical evidence on metronomic dosing in controlled clinical trials: a systematic literature review.

2020

Introduction: Metronomic dosing is used to give continuous chemotherapy at low doses. The low doses have minimal side effects and may enable cancer treatment to be remodeled toward the management o...

medicine.medical_specialtymedicine.medical_treatmentAntineoplastic Agents030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineClinical Trials Phase II as TopicNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansRadiology Nuclear Medicine and imagingDosingIntensive care medicineRandomized Controlled Trials as TopicChemotherapybusiness.industryLow doseHematologyGeneral MedicineProgression-Free SurvivalCancer treatmentClinical trialSurvival RateSystematic reviewOncologyClinical Trials Phase III as TopicClinical evidence030220 oncology & carcinogenesisAdministration MetronomicbusinessActa oncologica (Stockholm, Sweden)
researchProduct

Rationale and design of the EMBRACE STEMI Study: A phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability …

2012

Background Although significant efforts have been made to improve ST-segment elevation myocardial infarction (STEMI) outcomes by reducing symptom-onset-to-reperfusion times, strategies to decrease the clinical impact of ischemic reperfusion injury have demonstrated limited success. Bendavia, an intravenously administered mitochondrial targeting peptide, has been shown to reduce myocardial infarct size and attenuate coronary no-reflow in experimental modelswhen given before reperfusion. Design The EMBRACE STEMI study is a phase 2a, randomized, double-blind, placebo-controlled trial enrolling 300 patients with a first-time anterior STEMI and an occluded proximal or mid–left anterior descendin…

medicine.medical_specialtymedicine.medical_treatmentMyocardial InfarctionPlacebo-controlled studyMyocardial Reperfusion InjuryPlaceboClinical Trials Phase II as TopicInternal medicinemedicineClinical endpointHumansInfusions Intra-ArterialST segmentcardiovascular diseasesMyocardial infarctionRandomized Controlled Trials as Topicbusiness.industryPatient SelectionPercutaneous coronary interventionmedicine.diseaseResearch DesignConventional PCICardiologyNo-Reflow PhenomenonStentsCardiology and Cardiovascular MedicinebusinessOligopeptidesReperfusion injuryAmerican Heart Journal
researchProduct